Feeds
20859 items (20859 unread) in 74 feeds
Acinar Cell Carcinoma
(201 unread)
Acinic Cell Carcinoma
(104 unread)
Adenoid Cystic Carcinoma
(367 unread)
Adrenal Gland Cancer
(1718 unread)
Ampulla Of Vater
(213 unread)
Anal Cancer
(1799 unread)
Angiosarcoma
(359 unread)
Appendix Cancer
(450 unread)
Bile Duct Cancer
(2698 unread)
Brain and CNS
(2597 unread)
Carcinoid
(671 unread)
Endocrine/Neuroendocrine
(2404 unread)
Gall Bladder Cancer
(1146 unread)
Hemangioendothelioma
(506 unread)
Hepatoblastoma
(366 unread)
Pancreas
(416 unread)
Phyllodes
(215 unread)
PMP and Mucinous Tumors
(242 unread)
Rhabdomyosarcoma
(772 unread)
Sarcoma
(3615 unread)
Google - Rare CNS Tumor (100 unread)
-
Covid-19 roundup: Both AstraZeneca and EC claim a win in legal case over vaccine delay; South Korea to mix-and-match vaccines — report - Endpoints News
Posted: June 18th, 2021, 9:26am GMT
-
Biotech founder placed on leave as $400M Alzheimer's startup idea comes under scrutiny - Endpoints News
Posted: June 18th, 2021, 9:20am GMT
-
After roller-coaster week, CRL forces a reckoning on Orphazyme investors — inflated shares plummet - Endpoints News
Posted: June 18th, 2021, 9:12am GMT
-
Nerve Rejuv Reviews: Legit Nerve Health Support... - Federal Way Mirror
Posted: June 18th, 2021, 6:30am GMT
Nerve Rejuv Reviews: Legit Nerve Health Support... Federal Way Mirror -
In a move to boost its natural killer candidates, Senti Bio will build out its own San Francisco manufacturing facility - Endpoints News
Posted: June 17th, 2021, 11:59am GMT
-
Rick Klausner's crew of T cell specialists wraps $425M IPO, hitting Nasdaq alongside Verve, Molecular Partners - Endpoints News
Posted: June 17th, 2021, 8:27am GMT
-
Abstract Published in Neuro-Oncology Demonstrates Curtana Pharmaceuticals' CT-179 Prolonged Event-free Survival in an Animal Model of Medulloblastoma - BioSpace
Posted: June 16th, 2021, 2:09pm GMT
-
Deadly Facial Tumors Spur Tasmanian Devil Evolution: Study - The Scientist
Posted: June 16th, 2021, 1:55pm GMT
-
Plus Therapeutics Announces DSMB Approval to Proceed into - GlobeNewswire
Posted: June 16th, 2021, 9:30am GMT
-
SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in ... - The Bakersfield Californian
Posted: June 16th, 2021, 8:30am GMT
SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in ... The Bakersfield Californian -
SpringWorks Therapeutics Announces Initiation of Phase 1/2 - GlobeNewswire
Posted: June 16th, 2021, 8:30am GMT
-
When does a throbbing headache actually show signs of a brain tumor? - Pennsylvanianewstoday.com
Posted: June 16th, 2021, 8:28am GMT
When does a throbbing headache actually show signs of a brain tumor? Pennsylvanianewstoday.com -
10 Startups to Watch - Clinical OMICs News
Posted: June 16th, 2021, 5:54am GMT
10 Startups to Watch Clinical OMICs News -
Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemot | JIR - Dove Medical Press
Posted: June 15th, 2021, 9:16pm GMT
Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemot | JIR Dove Medical Press -
When Is a Headache a Sign of a Brain Tumor? Doctors Explain - Prevention.com
Posted: June 15th, 2021, 7:31pm GMT
When Is a Headache a Sign of a Brain Tumor? Doctors Explain Prevention.com -
Agricultural Biological Control Agents Market Professional Survey, Financial Overview, Emerging Applications and Forecast to 2027 | BASF, Bayer, AgBiome, Certis USA, United Phosphorus – Clark County Blog - Clark County Blog
Posted: June 15th, 2021, 5:44pm GMT
-
Umoja raises $210M series B to move immunotherapy program to the clinic - BioWorld Online
Posted: June 15th, 2021, 3:00pm GMT
-
Burgeoning Breast Cancer Landscape Brings Hope for a Brighter Future - OncLive
Posted: June 15th, 2021, 1:13pm GMT
-
Tackle Kids Cancer Raises $80,000 in Inaugural Virtual 5K to Support Pediatric Cancer Research and Patient Care Programs - Network News, News, Press Releases, Press Releases - Hackensack Meridian Health
Posted: June 15th, 2021, 12:31pm GMT
-
Abstract Published in Neuro-Oncology Demonstrates Curtana Pharmaceuticals' CT-179 Prolonged Event-free Survival in an Animal Model of Medulloblastoma - Digital Journal
Posted: June 15th, 2021, 10:35am GMT
-
CRISPR Therapeutics takes a swing at ALS gene editing in discovery deal with AAV upstart Capsida - Endpoints News
Posted: June 15th, 2021, 9:41am GMT
-
Tumefactive demyelination appearing as multiple cystic brain lesions - DocWire News
Posted: June 15th, 2021, 4:00am GMT
-
DELYTACT Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant Glioma | DNA RNA and Cells | News Channels - PipelineReview.com
Posted: June 12th, 2021, 2:55pm GMT
-
5 Buy-Rated Stocks Trading Below $10 With Outstanding Upside Potential - 24/7 Wall St.
Posted: June 12th, 2021, 8:05am GMT
-
Months after FDA rejection, Sanofi touts pivotal win for rare disease drug sutimlimab as it preps to refile - Endpoints News
Posted: June 11th, 2021, 11:37am GMT
-
Vertex and CRISPR Therapeutics unveil more positive gene therapy data, but busulfan again casts a shadow over the field - Endpoints News
Posted: June 11th, 2021, 9:23am GMT
-
UPDATED: Vertex strikes out on its latest big shot at a rare genetic disease. But they're going to keep on swinging - Endpoints News
Posted: June 11th, 2021, 12:36am GMT
-
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented - GlobeNewswire
Posted: June 10th, 2021, 2:54pm GMT
-
A second adcomm member abandons his post in aftermath of controversial aducanumab decision - Endpoints News
Posted: June 10th, 2021, 1:37pm GMT
-
Molecular Profiling in Pediatric Cancer Trials Continues to Prove Valuable for Treatment Matching - Precision Oncology News
Posted: June 10th, 2021, 12:43pm GMT
-
The Herb Column: CBD is for Cats, Birds and Dogs - Comstock's Magazine
Posted: June 10th, 2021, 11:48am GMT
The Herb Column: CBD is for Cats, Birds and Dogs Comstock's Magazine -
Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference - StreetInsider.com
Posted: June 10th, 2021, 9:35am GMT
-
Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference - GlobeNewswire
Posted: June 10th, 2021, 9:30am GMT
-
A Medicxi-backed startup looks to tackle treatment-resistant blood cancers, and it's going after AML first - Endpoints News
Posted: June 10th, 2021, 9:00am GMT
-
Versant-backed Bright Peak sets a date to bring its IL-2 into the clinic — but all eyes are on an IPO after latest mega-round drops - Endpoints News
Posted: June 10th, 2021, 5:21am GMT
-
Synthekine nabs megaround in bid to edge out Merck, Sanofi in IL-2 sprint - Endpoints News
Posted: June 10th, 2021, 5:03am GMT
-
Study Sheds Light on Treatment Options for Medulloblastoma - OncoZine
Posted: June 10th, 2021, 5:00am GMT
-
Fore Bio lands in Philadelphia – PharmaLive - PharmaLive
Posted: June 10th, 2021, 5:00am GMT
Fore Bio lands in Philadelphia – PharmaLive PharmaLive -
Black fungus: 764 cases, 49 deaths reported in Indore - ETHealthworld.com
Posted: June 10th, 2021, 2:57am GMT
Black fungus: 764 cases, 49 deaths reported in Indore ETHealthworld.com -
Research news tip sheet: Story ideas from Johns Hopkins Medicine - EurekAlert
Posted: June 9th, 2021, 7:22pm GMT
-
TRK Inhibitor Proves Beneficial in Primary CNS Tumors - MedPage Today
Posted: June 9th, 2021, 7:17pm GMT
TRK Inhibitor Proves Beneficial in Primary CNS Tumors MedPage Today -
Plus Therapeutics to Participate in BIO Digital Conference - StreetInsider.com
Posted: June 9th, 2021, 6:20pm GMT
Plus Therapeutics to Participate in BIO Digital Conference StreetInsider.com -
CORE Diagnostics receives International Accreditation from College of American Pathologists (CAP) - ETHealthworld.com
Posted: June 9th, 2021, 12:23pm GMT
-
Long-Term Efficacy Data Continues to Support Larotrectinib Use for Tumor With NTRK Fusions - Cancer Network
Posted: June 9th, 2021, 11:09am GMT
-
Covid more likely to spread indoors through maskless interaction - ETHealthworld.com
Posted: June 9th, 2021, 7:05am GMT
Covid more likely to spread indoors through maskless interaction ETHealthworld.com -
AMR -- The insidious and silent pandemic ‘in making’ - ETHealthworld.com
Posted: June 9th, 2021, 2:58am GMT
AMR -- The insidious and silent pandemic ‘in making’ ETHealthworld.com -
Study shows how novel drug screen can individualise cancer therapy - ETHealthworld.com
Posted: June 9th, 2021, 2:36am GMT
Study shows how novel drug screen can individualise cancer therapy ETHealthworld.com -
Covid-19 vaccines for kids: FDA spells out questions on immunobridging, safety followup ahead of adcomm - Endpoints News
Posted: June 8th, 2021, 9:57pm GMT
-
Prioritising Aspects of Brain Tumour Care during Covid-19 in Managing Cancer Patients - ETHealthworld.com
Posted: June 8th, 2021, 10:39am GMT
-
Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test - Endpoints News
Posted: June 8th, 2021, 10:05am GMT
-
Partners release trial results of Hanmi's cancer drugs in ASCO 2021 - Korea Biomedical Review
Posted: June 8th, 2021, 5:27am GMT
Partners release trial results of Hanmi's cancer drugs in ASCO 2021 Korea Biomedical Review -
A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first - Endpoints News
Posted: June 8th, 2021, 5:00am GMT
-
Flagship and Khosla Ventures team up for biotech's latest SPAC, with Valo Health winning a blank check ticket to Nasdaq - Endpoints News
Posted: June 8th, 2021, 5:00am GMT
-
ViaCyte adds to the war chest in what looks like an IPO-bound effort to bring regenerative medicine to diabetes - Endpoints News
Posted: June 8th, 2021, 5:00am GMT
-
Salvaging 'ugly fruit': After a series of protein degradation bets, Versant turns to protein stabilization platform out of Columbia - Endpoints News
Posted: June 8th, 2021, 5:00am GMT
-
Sid Mukherjee's Vor taps a CAR-T development partner to strap to its attempt at better stem cell transplants - Endpoints News
Posted: June 8th, 2021, 5:00am GMT
-
BeiGene dives in on natural killer cells with discovery pact for small biotech's stem cell-based platform - Endpoints News
Posted: June 8th, 2021, 5:00am GMT
-
Merck & Co., Inc. (MRK) Management Presents at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Conference (Transcript) - Seeking Alpha
Posted: June 8th, 2021, 3:42am GMT
-
Mucormycosis In Covid-19 Patients: What happens if Black Fungus Attacks the Brain? - TheHealthSite
Posted: June 8th, 2021, 3:12am GMT
-
Just how sadly misguided is the FDA on aducanumab? - Endpoints News
Posted: June 8th, 2021, 10:20pm GMT
Just how sadly misguided is the FDA on aducanumab? Endpoints News -
From protein degradation to 'toad venom': Another five biotechs will make the Nasdaq shuffle after filing SEC paperwork - Endpoints News
Posted: June 7th, 2021, 8:39pm GMT
-
FDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field - Endpoints News
Posted: June 7th, 2021, 8:39pm GMT
-
#ASCO21: AstraZeneca takes a swing at J&J and AbbVie's Imbruvica with long-term data from head-to-head trial - Endpoints News
Posted: June 7th, 2021, 1:10pm GMT
-
Pediatric Patients With RET-Altered Tumors Experience Tumor Responses With Selpercatinib - Cancer Network
Posted: June 7th, 2021, 12:11pm GMT
-
New PPARgamma agonist shows promise in neurodegenerative diseases - BioWorld Online
Posted: June 7th, 2021, 11:00am GMT
-
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient - PRNewswire
Posted: June 7th, 2021, 10:00am GMT
-
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient - ACROFAN USA
Posted: June 7th, 2021, 9:00am GMT
-
Selpercatinib Shows Encouraging Antitumor Activity in Pediatric Patients with RET-Altered Solid Tumors - Targeted Oncology
Posted: June 6th, 2021, 8:14pm GMT
-
Selpercatinib Elicits Encouraging Antitumor Activity in Pediatric RET-Altered Solid Tumors - OncLive
Posted: June 6th, 2021, 5:06pm GMT
-
MAPK Expression Does Not Drive Selumetinib Response in Refractory Pediatric and AYA Cancers - Cancer Network
Posted: June 5th, 2021, 9:35pm GMT
-
Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors - OncLive
Posted: June 5th, 2021, 9:30pm GMT
-
Robust Responses Seen with Larotrectinib in TRK Fusion Cancer - Targeted Oncology
Posted: June 5th, 2021, 4:04pm GMT
Robust Responses Seen with Larotrectinib in TRK Fusion Cancer Targeted Oncology -
Larotrectinib Elicits Robust Responses in TRK Fusion Cancer - OncLive
Posted: June 5th, 2021, 3:44pm GMT
-
The Domino Effect of long Covid on brain health - ETHealthworld.com
Posted: June 5th, 2021, 5:23am GMT
The Domino Effect of long Covid on brain health ETHealthworld.com -
#ASCO21: Eli Lilly-partnered Merus reveals new data for NRG1 fusion cancers including pancreatic and NSCLC - Endpoints News
Posted: June 4th, 2021, 2:00pm GMT
-
#ASCO21: Bristol Myers' solo, dual I/O regimens best chemo alone — with one exception — in first-line esophageal patients - Endpoints News
Posted: June 4th, 2021, 5:00am GMT
-
Analyzing tumor microenvironment at single cell level sheds light on metastatic melanoma outcomes - Medical Xpress
Posted: June 3rd, 2021, 6:15pm GMT
-
Analyzing tumor microenvironment at single cell level sheds light on metastatic melanoma outcomes - EurekAlert
Posted: June 3rd, 2021, 5:32pm GMT
-
Analyzing the Tumor Microenvironment at the Single Cell Level Sheds Light on Metastatic Melanoma Outcomes, Moffitt Study Shows - Newswise
Posted: June 3rd, 2021, 4:10pm GMT
-
Amryt earns a priority review in a rare disease that makes patients' skin fragile as butterfly wings - Endpoints News
Posted: June 3rd, 2021, 1:12pm GMT
-
UPDATED: Corey Goodman's venBio closes latest VC fund — this time to the tune of $550M — with a dozen or more investments on deck - Endpoints News
Posted: June 3rd, 2021, 12:19pm GMT
-
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors - StreetInsider.com
Posted: June 3rd, 2021, 10:04am GMT
-
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors - PRNewswire
Posted: June 3rd, 2021, 10:00am GMT
-
Exicure, Inc. Announces Participation in Upcoming Conferences - Business Wire
Posted: June 3rd, 2021, 9:00am GMT
-
Exicure, Inc. Announces Participation in Upcoming Conferences - Yahoo Finance
Posted: June 3rd, 2021, 9:00am GMT
-
Single-Cell Insights on Inaccessible Tumor Environments Expand Therapeutic Options - Genetic Engineering & Biotechnology News
Posted: June 3rd, 2021, 6:00am GMT
Single-Cell Insights on Inaccessible Tumor Environments Expand Therapeutic Options Genetic Engineering & Biotechnology News -
Almost a decade after identifying a new class of RNA, a group of scientists sparks interest from Takeda Ventures - Endpoints News
Posted: June 3rd, 2021, 5:00am GMT
-
New Fund for Early-Stage Life Sciences, Microscopy for Protein Dynamics: Follow the Money - Bio-IT World
Posted: June 3rd, 2021, 3:09am GMT
-
Five more biotechs file their SEC paperwork as the IPO Class of 2021 swells to 60 - Endpoints News
Posted: June 3rd, 2021, 1:07am GMT
-
Scientists discover a way to stop Ewing sarcoma cells from spreading - PhillyVoice.com
Posted: June 2nd, 2021, 3:06pm GMT
-
Innovation Fuels Breakthroughs for Rare Cancers - OncLive
Posted: June 2nd, 2021, 12:11pm GMT
-
Ard Ri CNS stepping up for Nahyan's 'High 5' Campaign - Meath Chronicle
Posted: June 2nd, 2021, 10:43am GMT
Ard Ri CNS stepping up for Nahyan's 'High 5' Campaign Meath Chronicle -
Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021 - Monterey County Weekly
Posted: June 2nd, 2021, 10:42am GMT
-
Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021 - PRNewswire
Posted: June 2nd, 2021, 10:00am GMT
-
Relying on an ultra-rare variant, David Liu unveils a new approach to editing sickle cell - Endpoints News
Posted: June 2nd, 2021, 5:00am GMT
-
circPRDM2/miR-760/EZH2 axis in enhancing DXR resistance | CMAR - Dove Medical Press
Posted: June 1st, 2021, 7:04pm GMT
circPRDM2/miR-760/EZH2 axis in enhancing DXR resistance | CMAR Dove Medical Press -
Sanofi slashes another program for key molecule, while keeping hopes in handful of rare diseases - Endpoints News
Posted: June 1st, 2021, 9:00am GMT
-
These 5 Stocks Surged in the Past Week: Should You Buy? - Nasdaq
Posted: June 1st, 2021, 6:36am GMT
-
EULAR 2021: New Data from UCB's Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age - PR Newswire UK
Posted: May 31st, 2021, 9:00pm GMT
-
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis | OARRR - Dove Medical Press
Posted: May 31st, 2021, 8:44pm GMT